28.07.2021

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

Dr. Antonia reports receiving fees for serving on an advisory board from AstraZeneca; Dr. Villegas, receiving fees for serving on a speakers’ bureau from Celgene, Alexion, and Bristol-Myers Squibb; Dr. Hui, receiving fees for serving on an advisory board and lecture fees from AstraZeneca and Merck Sharp Dohme, fees for serving on an advisory board from Novartis and Pfizer, and lecture fees from Bristol-Myers Squibb and Boehringer Ingelheim; Dr. Chiappori, receiving fees for serving on a speakers’ bureau from Genentech, Merck, Pfizer, Boehringer Ingelheim, and Celgene, fees for serving on a speakers’ bureau and advisory board from Takeda and Novartis, and fees for serving on an advisory board from Bristol-Myers Squibb; Dr. de Wit, receiving lecture fees from AstraZeneca; Dr. Mekhail, receiving grant support and fees for serving on a speakers’ bureau from AstraZeneca; Dr. Planchard, receiving fees for serving on an advisory board from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Merck Sharp Dohme, Pfizer, and Novartis; Dr. Kim, receiving grant support from AstraZeneca, Roche, Merck, Bristol-Myers Squibb and Ono Pharmaceutical, and Boehringer Ingelheim; Dr. Karapetis, receiving travel support from AstraZeneca; Dr. Hiret, receiving consulting fees and advisory fees from Roche, AstraZeneca, and Boehringer Ingelheim; Dr. Kubota, receiving grant support and honoraria from Daiichi Sankyo, Boehringer Ingelheim, and Taiho, and honoraria from Eli Lilly, Merck Sharp Dohme, Bristol-Myers Squibb, Amgen, Ono Pharmaceutical, Novartis, and Chugai Pharmaceutical; Dr. Gray, receiving grant support and advisory fees from AstraZeneca; Dr. Paz-Ares, receiving advisory fees from AstraZeneca, Pfizer, Bristol-Myers Squibb, Merck Sharp Dohme, Lilly, Roche, Merck Serono, Novartis, and Boehringer Ingelheim; Dr. de Castro Carpeño, receiving fees for serving on an advisory board and lecture fees from AstraZeneca, Boehringer Ingelheim, and Merck Sharp Dohme, fees for serving on an advisory board, lecture fees, and travel support from Bristol-Myers Squibb and Roche, and fees for serving on an advisory board from Merck; Dr. Melillo, being employed by AstraZeneca; Dr. Jiang, being employed by and holding stock options in AstraZeneca; Dr. Huang, being employed by and owning stock in AstraZeneca; and Dr. Dennis, being employed by and owning stock in AstraZeneca. No other potential conflict of interest relevant to this article was reported.

This article was published on September 8, 2017, at NEJM.org.

We thank all the patients and their families and caregivers for their participation in this study; Marc Ballas, M.D., M.P.H., formerly of AstraZeneca, and Louis Viviers, M.D., of QuintilesIMS for their contributions to the study; and Andrew Gannon, M.S., and Lietta Nicolaides, Ph.D., of CircleScience, an Ashfield Company, for medical-writing support.

Leave a Reply

Your email address will not be published. Required fields are marked *